AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical study titled A Phase I Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 Following Repeat Dose Administration in Participants With Overweight or Obesity. The study aims to assess the safety and effectiveness of AZD6234, a new drug intended to aid weight management in overweight or obese individuals.
The intervention involves administering AZD6234, a drug delivered via subcutaneous injection, to participants in various cohorts. The purpose is to evaluate its safety and pharmacological effects compared to a placebo.
This interventional study is randomized and follows a sequential intervention model with single masking for participants. The primary goal is treatment, focusing on the drug’s impact on weight management.
The study began on November 13, 2023, with an estimated completion date in 2025. The most recent update was submitted on July 15, 2025, indicating ongoing progress.
For investors, this study could influence AstraZeneca’s stock performance positively if results show significant efficacy and safety, potentially boosting investor confidence. In the competitive pharmaceutical industry, advancements in obesity treatment are highly sought after, which could place AstraZeneca ahead of its competitors.
The study is currently active but not recruiting, with further details accessible on the ClinicalTrials portal.